Skip to content

DBV Technologies DBVT Treasury Stock

Treasury Stock at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$19.41B+19.7%

Other financials

Income statement

See full
Revenue$900.0K+12.5%
Operating income-$47.9M-80.1%
Net income-$47.6M-75.6%
EPS (diluted)-$0.11+57.7%

Balance sheet

See full
Cash & equivalents$229.2M+1,668%
Total debt$6.1M-15.7%
Total equity$207.9M+7,069%
Total assets$266.4M+427%

Cash flow

See full
Operating cash flow-$49.1M-149%
CapEx$400.0K
Free cash flow-$49.5M-151%

Valuation

See full
Market cap$923.31M+269%
Enterprise value$700.21M+188%
P/S159.6×+89.0×

Profitability

See full
Operating margin-2,910.4%-265pp
Net margin-2,895.4%-257pp
FCF margin-2,619.5%+69.9pp

Returns & leverage

See full
Return on equity-158.9%-26.4pp
Debt / equity-2.5×
Current ratio4.8×+4.0×

Where this comes from

Reported directly by DBV Technologies in its filing.

Tagged under the XBRL concept us-gaap:TreasuryStockCommonValue.

The official record: DBV Technologies’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about DBV Technologies's treasury stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is DBV Technologies's treasury stock?
DBV Technologies (DBVT) reported treasury stock of $1M in Q1 2026.
How has DBV Technologies's treasury stock changed year-over-year?
DBV Technologies's treasury stock decreased by 20.8% year-over-year, from $1.26M to $1M.
What is the long-term trend for DBV Technologies's treasury stock?
Over 5 years (2020 to 2025), DBV Technologies's treasury stock has grown at a -7.3% compound annual growth rate (CAGR), from $1.17M to $800K.
What does treasury stock mean?
Shares repurchased by the company and held in treasury, reducing equity. Recorded at cost and presented as a negative equity component.